Montserrat Pujol

List of Publications by Year
in descending order

44 papers	608 citations	687363 13 h-index	642732 23 g-index
45 all docs	45 docs citations	45 times ranked	776 citing authors

#	Article	IF	Citations
1	Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. International Journal of Molecular Sciences, 2021, 22, 4983.	4.1	40
2	Dexibuprofen Biodegradable Nanoparticles: One Step Closer towards a Better Ocular Interaction Study. Nanomaterials, 2020, 10, 720.	4.1	44
3	Lipid domains in LB films and giant vesicles to study GBV-C peptides interaction in the context of HIV-1 FP inhibition at membranes. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2019, 578, 123620.	4.7	0
4	Characterization and lipid phase effect on the interaction of GBV-C E2-derived peptide, P6-2VIR576, with lipid membranes relating it with the HIV-1 FP inhibition. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2018, 554, 187-196.	4.7	3
5	Interaction of the GBV-C E2-derived peptide, P6-2VIR576, with anionic phospholipid membranes. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2017, 532, 483-492.	4.7	11
6	Langmuir monolayers and Differential Scanning Calorimetry for the study of the interactions between camptothecin drugs and biomembrane models. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 422-433.	2.6	15
7	Tryptophan-containing lipopeptide antibiotics derived from polymyxin B with activity against Gram positive and Gram negative bacteria. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 333-343.	2.6	31
8	A study of HIV-1 FP inhibition by GBV-C peptides using lipid nano-assemblies. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2015, 480, 184-190.	4.7	5
9	Membrane interaction of a new synthetic antimicrobial lipopeptide sp-85 with broad spectrum activity. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2015, 480, 307-317.	4.7	12
10	Surface behavior of peptides from E1 GBV-C protein: Interaction with anionic model membranes and importance in HIV-1 FP inhibition. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 392-407.	2.6	8
11	A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1. European Journal of Medicinal Chemistry, 2014, 86, 589-604.	5.5	12
12	Modification of FP-HIV activity by peptide sequences of GB virus C: A biophysical approach. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 1274-1280.	2.6	3
13	XV International Symposium on Luminescence Spectrometryâ€"ISLS 2012. Analytical and Bioanalytical Chemistry, 2013, 405, 3915-3916.	3.7	0
14	Physicochemical characterization of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide: Interaction with model membranes. International Journal of Pharmaceutics, 2012, 436, 593-601.	5.2	7
15	Effect of E1(64â€"81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with membrane models. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 2178-2188.	2.6	17
16	Biophysical Investigations of GBVâ€€ E1 Peptides as Potential Inhibitors of HIVâ€‚ Fusion Peptide. ChemPhysChem, 2011, 12, 2816-2822.	2.1	12
17	Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of GB virus C. Journal of Colloid and Interface Science, 2011, 360, 124-131.	9.4	22
18	A Langmuir Monolayer Study of the Interaction of E1(145â"162) Hepatitis G Virus Peptide with Phospholipid Membranes. Journal of Physical Chemistry B, 2010, 114, 448-456.	2.6	28

#	Article	IF	Citations
19	Fluorescence study of the dynamic interaction between E1(145â€“162) sequence of hepatitis GB virus C and liposomes. Analytical and Bioanalytical Chemistry, 2009, 394, 1003-1010.	3.7	12
20	Surface behaviour and peptideâ€“lipid interactions of the E1(3-17)R and E1(3-17)G peptides from E1 capside protein of GBV-C/HGV virus. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2008, 321, 175-180.	4.7	7
21	Gram-Negative Outer and Inner Membrane Models:Â Insertion of Cyclic Cationic Lipopeptides. Journal of Physical Chemistry B, 2007, 111, 551-563.	2.6	123
22	Polymyxin B-lipid interactions in Langmuir-Blodgett monolayers ofEscherichia coli lipids: A thermodynamic and atomic force microscopy study. Biopolymers, 2004, 75, 480-490.	2.4	35
23	Physicochemical studies of E1(53-66) synthetic peptide by phospholipid monolayers and differential scanning calorimetry. European Physical Journal Special Topics, 2004, 113, 39-42.	0.2	0
24	Interaction study of three overlapping synthetic peptides belonging to E2 protein of GBV-C/HGV with liposomes as biomembrane models. European Physical Journal Special Topics, 2004, 122, 211-215.	0.2	0
25	Influence of polymyxins on the structural dynamics of Escherichia coli lipid membranes. Talanta, 2003, 60, 225-234.	5.5	20
26	Interaction of polymyxin B and A deacilated derivative with monolayers of bacterial lipids. European Physical Journal Special Topics, 2001, 11, Pr10-227-Pr10-232.	0.2	0
27	Membrane fusion by an RGD-containing sequence from the core protein VP3 of hepatitis A virus and the RGA-analogue: Implications for viral infection. Biopolymers, 2001, 58, 63-77.	2.4	11
28	Membrane fusion induced by a lipopeptidic epitope from VP3 capside protein of hepatitis A virus. Luminescence, 2001, 16, 135-143.	2.9	6
29	Physicochemical studies of hepatitis A virus recombinant proteins: interaction with monolayers as membrane models. Materials Science and Engineering C, 1999, 8-9, 481-485.	7.3	0
30	Miscibility of the Hepatocyte Membrane Lipids at the Air/Water Interface and Interaction with the Sequence (110â^'121) of the Capsid Protein VP3 of Hepatitis A Virus. Langmuir, 1999, 15, 1101-1107.	3.5	12
31	pH-induced destabilization of lipid bilayers by a peptide from the VP3 protein of the capsid of hepatitis A virusâ€. Analyst, The, 1998, 123, 2251-2256.	3.5	12
32	Stability Study of Epirubicin in Nacl 0.9% Injection. Annals of Pharmacotherapy, 1997, 31, 992-995.	1.9	4
33	Physicochemical study of laminin-related peptides. Supramolecular Science, 1997, 4, 449-453.	0.7	3
34	Degradation pathway of carboplatin in aqueous solution. International Journal of Pharmaceutics, 1997, 146, 263-269.	5.2	16
35	Stability Study of Carboplatin in Aqueous Solution and Under Illumination by High Performance Liquid Chromatography. Biomedical Chromatography, 1997, 11, 119-120.	1.7	6
36	Interaction with Phospholipid Mono- and Bi-layers of HAV-VP3 (102-121) Sequence by Using Spectroscopic Techniques. Biomedical Chromatography, 1997, 11, 121-123.	1.7	3

#	Article	IF	Citations
37	Synthesis, lipophilic derivatization and interaction with liposomes of HAVâ€“VP3 (102â€“121) sequence by using spectroscopic techniques. Analyst, The, 1996, 121, 1583-1588.	3.5	26
38	Degradation kinetics of ifosfamide in aqueous solution. International Journal of Pharmaceutics, 1996, 139, 249-253.	5.2	8
39	Influence of alkyl length in the miscibility of several types of lecithins. Interaction of doxorubicin with these membrane models. Thin Solid Films, 1996, 284-285, 723-726.	1.8	1
40	Stability of carboplatin in 5% glucose solution in glass, polyethylene and polypropylene containers. Journal of Pharmaceutical and Biomedical Analysis, 1994, 12, 81-84.	2.8	16
41	Stability of aqueous carboplatin solutions under illumination. Monatshefte FÃ¼r Chemie, 1993, 124, 1077-1081.	1.8	9
42	Stability of ifosfamide in 0.9% sodium chloride solution or water for injection in a portable i.v. pump cassette. American Journal of Health-System Pharmacy, 1992, 49, 1137-1139.	1.0	0
43	HPLC determination of azlocillin sodium for stability studies. International Journal of Pharmaceutics, 1990, 58, 103-106.	5.2	2
44	Ampicillin polymers: identification by gel-filtration chromatography. International Journal of Pharmaceutics, 1988, 41, 241-244.	5.2	6